You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Microneedle Delivery of Zanamivir for Treatment of Influenza Infections
SBC: TSRL, INC. Topic: NIAIDAbstract Yearly influenza epidemics strike millions of peoplecausing up todeathsFatality caused by most seasonal influenza viruses is ltbut with significant mortality in the young and the elderly populationsWhen a new pathogenic influenza strain enters the populationa pandemic could kill tens of millions of people with a negative economic impact estimated to be overbillion dollarsInfluenza virus i ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
New Technologies for Therapist Training and Patient Engagement in Behavioral Parent Training
SBC: KOBAK, KENNETH A Topic: 104Project Summary Abstract Behavioral parent trainingBPTis the gold standard treatment for disruptive behavior in preschool and elementary school age childrenDespite clear empirical evidence that it is effectiveadoption rates by practitioners remains woefully low due in part to a shortage of clinicians trained in BPTIn additioneven when BPT is administeredit is often done incorrectlyThe current stud ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Vagus Nerve Stimulation Treatment for Asthmatic Bronchoconstriction
SBC: ROSELLINI SCIENTIFIC, LLC Topic: NHLBIProject Summary The Specific Aim of this proposal is to test the feasibility of using vagus nerve stimulation VNS for treating asthma related airway constriction that is refractory to current treatments There are approximately million people with asthma in the US About percent of these asthma sufferers experience early and late phase severe asthmatic bronchoconstriction that is refract ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Biomaterials for mRNA based cellular reprogramming
SBC: STEM PHARM, INCORPORATED Topic: 100Project Summary Abstract Induced pluripotent stem cells iPSCs hold great promise in the areas of disease modeling and regenerative medicine and as a result have unique commercial potential There are currently more than ongoing clinical trials in stem cell therapies including the first in human trial using human iPSC derived retinal pigment epithelial cells to treat ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
OpenBeds: Improving the Delivery of Care for Patients with Drug Addiction
SBC: Openbeds Inc. Topic: NIDAThere is an urgent need for more effective mechanisms that leverage current technologies and best practices to both identify capacity and refer patients to drug treatment facilitiesThe applicant organizationOpenBeds Incis partnering with the non profit MESH Coalitionthree of the largest health care systems offering drug treatment in Indiana and the Indiana Division of Mental Health and AddictionDM ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics' reduced genome E coli strains
SBC: SCARAB GENOMICS, LLC Topic: NIAIDScarab Genomics goal is to commercialize carrier proteins for conjugate vaccine manufacture This proposal focuses on two bacterial carrier proteins that have been approved by the FDA and that are in use in pre clinical and clinical studies Exoprotein A EPA from Pseudomonas aeruginosa and Protein D PD from non typeable Haemophilus influenzae These proteins are difficult to make by the conve ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Harvesting specific plant metabolites from hairy root cultures using magnetized nanoparticles
SBC: NAPROGENIX, INC. Topic: RAbstractPlant cell cultures are becoming a commercially valuable source of pharmaceuticalsparticularly those that are too complex for economical chemical synthesisFor example Phyton Biotechin Germanyhas achieved great commercial success by generating taxoids for Paclitaxel production in sterile plant cell bioreactorsHoweverthe efficiency of these systems is limited by the loss in viability of the ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Geostatistical software for space-time interpolation and uncertainty modeling
SBC: BIO-ANALYTICS, INC. Topic: NIEHSDESCRIPTIONprovided by applicantA key component in any investigation of association and or cause effect relationships between the environmente gair pollutionheat wavesand health outcomese gasthmaheart diseasecanceris the availability of accurate models of exposure at the same geographical scale and temporal resolution as the health outcomesThe computation of human exposure is particularly challeng ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
De-risking ONL1204 to enable venture capital investment for first-in-human clinical trials
SBC: ONL Therapeutics, Inc. Topic: NEIPROJECT SUMMARYABSTRACTRetinal degenerative disease and injury are among the leading causes of irreversible vision loss and blindness in the United States and the developed worldaffecting hundreds of thousands of people every year and resulting in billions of dollars in added healthcare costs and lost productivityPhotoreceptor cell death is a consequence of many of these acute and chronic retinal ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of MTX for the Treatment of KRAS Mutant Colorectal Cancer
SBC: Mekanistic Therapeutics, LLC Topic: NCIPROJECT SUMMARY Mekanistic Therapeutics seeks to design discover and develop anti cancer agents that selectively inhibit multiple oncogenic pathways Its lead agent MTX was discovered in collaboration with the Leopold laboratory at University of Michigan MTX is a novel kinase inhibitor showing early promise for its therapeutic potential against solid cancers refractory to current treatm ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health